New Jersey, USA - 06 Feb `23A Clinical Research Study of VYN201 Ointment in Adults with Vitiligo


Official Title: A Phase 1, Single and Multiple Ascending Dose (SAD/MAD) Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of VYN201 in Healthy Volunteers and in Subjects with Non-Segmental Vitiligo (NSV)
Brief Summary: A Phase 1 study of VYN201 in Healthy Volunteers and Subjects with Non-Segmental Vitiligo
Detailed Description: Study VY2022-01 is an open-label study of VYN201 ointment given as single and multiple ascending doses in healthy volunteers, followed by multiple dosing of the three highest tolerated dosages in subjects with NSV. The healthy volunteer part has been completed and participants with vitiligo that qualify will be allocated to one of three treatment groups: low-dose VYN201, mid-dose VYN201, or high-dose VYN201.
Actual Study Start Date: November 2022
Estimated Study Completion Date: May 2023

Contact: Vyne Therapeutics
Tel: 1-800-775-7936

FAQOther Questions

  • Which diseases most commonly accompany vitiligo?

    According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...

  • PTSD in Vitiligo?

    Vitiligo has long been associated with disease-related discrimination, social stigma, self-isolation, lower self-esteem, embarrassment, anxiety, and depression.  These chronic ...